Alessandro Vinciguerra1,2, Benjamin Verillaud3, Michaël Eliezer4, Rachid Kaci5, Romain Kania3, Philippe Herman3. 1. Department of Surgical Sciences, Division of Otolaryngology, IRCCS San Raffaele Hospital, Vita-Salute University, Milan, Italy. vinciguerra.alessandro@hsr.it. 2. Otolaryngology Department, San Raffaele Hospital, Via Olgettina, 68, 20100, Milan, Italy. vinciguerra.alessandro@hsr.it. 3. Department of Otorhinolaryngology, Hôpital Lariboisière, Assistance Publique - Hôpitaux de Paris, Université de Paris, Inserm U1141, 2, rue Ambroise-Paré, 75010, Paris, France. 4. Department of Neuroradiology, Hôpital Lariboisière, Assistance Publique - Hôpitaux de Paris, Université de Paris, 2, rue Ambroise-Paré, 75010, Paris, France. 5. Department of Pathology, Hôpital Lariboisière, Assistance Publique - Hôpitaux de Paris, 2, rue Ambroise-Paré, 75010, Paris, France.
Abstract
PURPOSE: To describe and analyse functional treatment of temporal bone chondroblastoma (TBCh). METHODS: From January 2000 to June 2019, at the Department of Otorhinolaryngology, Hôpital Lariboisière, Paris, France, patients with TBCh were enrolled in this study. All cases routinely performed pre-operatory work-up including evaluation of performance status, audio-vestibular function test, ear endoscopy, contrasted CT scan and MRI of head and neck region; in one case we also performed an angio-CT scan. All patients underwent resection of the tumour with a "functional" approach RESULTS: Three male patients (mean age 46,6 years)-two primary tumours and one recurrence-were treated. In all three cases the tumour invaded the middle ear with a variable degree of hearing loss and infiltration of temporal bone structures. All surgeries were performed with a microscopic approach associated with open/endoscopic approach when necessary. Inner ear and facial nerve were speared in all cases and the TMJ was partially resected in 2 cases due to its moderate involvement. At present, after a mean follow-up of 103 months (range 40-225 months), only one case presented recurrence which has been successfully treated with radiotherapy. CONCLUSIONS: Our results of treatment suggest that functional surgery can be relevant in the management of TBCh since it is focused on both treatment of this pathology and maintenance of a good quality of life.
PURPOSE: To describe and analyse functional treatment of temporal bone chondroblastoma (TBCh). METHODS: From January 2000 to June 2019, at the Department of Otorhinolaryngology, Hôpital Lariboisière, Paris, France, patients with TBCh were enrolled in this study. All cases routinely performed pre-operatory work-up including evaluation of performance status, audio-vestibular function test, ear endoscopy, contrasted CT scan and MRI of head and neck region; in one case we also performed an angio-CT scan. All patients underwent resection of the tumour with a "functional" approach RESULTS: Three male patients (mean age 46,6 years)-two primary tumours and one recurrence-were treated. In all three cases the tumour invaded the middle ear with a variable degree of hearing loss and infiltration of temporal bone structures. All surgeries were performed with a microscopic approach associated with open/endoscopic approach when necessary. Inner ear and facial nerve were speared in all cases and the TMJ was partially resected in 2 cases due to its moderate involvement. At present, after a mean follow-up of 103 months (range 40-225 months), only one case presented recurrence which has been successfully treated with radiotherapy. CONCLUSIONS: Our results of treatment suggest that functional surgery can be relevant in the management of TBCh since it is focused on both treatment of this pathology and maintenance of a good quality of life.
Entities:
Keywords:
Chondroblastoma; Functional treatment; Middle ear surgery
Authors: Grégory Dran; Eric Niesar; Fanny Vandenbos; Georges Noel; Philippe Paquis; Michel Lonjon Journal: Childs Nerv Syst Date: 2006-11-18 Impact factor: 1.475
Authors: Alessandro Vinciguerra; Mario Turri-Zanoni; Benjamin Verillaud; Jean-Pierre Guichard; Luca Spirito; Apostolos Karligkiotis; Paolo Castelnuovo; Philippe Herman Journal: J Clin Med Date: 2022-07-24 Impact factor: 4.964